FARMINGTON, Conn., Oct. 31, 2012 /PRNewswire-iReach/ -- Learn about the global market for progressive ataxia and weakness disorder treatments and the factors that will influence the long-term development of neurodegenerative disorders in the pharmaceutical and biotechnology markets; learnabout the treatments that are most likely to be commercialized in the next five years.
(Photo: http://photos.prnewswire.com/prnh/20121031/CG03571)
Global Information Inc (GII) is announces the availability of four significant market research reports from our premium research partner BCC Research.
Pharmaceutical biotechnical companies, research institutes and physicians will find these new studies to be of interest.
Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders
The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.
Key areas of growth in the neurodegenerative disorder market include: Friedreich's ataxia, Gerstmann-Straussler-Scheinker disease, Machado-Joseph disease, amyotrophic lateral sclerosis, progressive bulbar palsy, hereditary spastic paraplegia, hereditary neuropathies and multiple sclerosis.
The report discusses applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology. The report also covers significant patents and their allotments in each category.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/bc252617-global-markets-treatments-syndromes-progressive.html
Focus on Progressive Ataxia
See original here:
Global Market for Neurodegenerative Disorder Treatments to Reach $23.5 billion in 2017, Weakness Disorders Treatments ...